>>But maybe it could be due to the pharmion deal. They just got bought out for 3billion plus they had sum new luekemia drug in the making that should b a blockbuster. Not sure if they are a direct comp. to IVPH though.<<
Vidaza is for MDS, so no, not a direct comp. I also think its blockbuster potential is overstated. Regarding your prior post, where did I get the updated INNO-406 info . . . ASH abstracts became available.
hematology.org
It is one of ten about INNO-406, but the others are all preclinical stuff. I didn't look at all of them; a quick scan indicated there was little new, and given the state of affairs, it doesn't really matter. I would guess Innovive employees won't be going to the meeting, unless they can thumb a ride to Atlanta and crash in someone else' hotel room. Not sure how they'd eat, though. Free continental breakfast? Luckily other presenters from better funded entities will be available to talk about the posters.
Obviously, they aren't in a position to negotiate from strength, but their stuff has to be worth something. The business development folks need to come up with a deal, like maybe a few million upfront for ex-US rights to 406 . . . something like that without giving away the whole farm. Wait, wait, I've got it! Rick, rkrw, tomato, can you talk 'em into buying Cadus or vice versa? Sigh. That's been the biofreak solution to such dilemmas for several years now. Makes too much sense to actually happen.
Whatever, my cost is a smidge over $2, it's a big enough chunk for me, and so I'm not getting any more until something fundamental gives.
Cheers, Tuck |
